Physician profile
Amar Narula
NPI 1811130081
$1,640.40
in general payments reported to CMS, 2019-2025
27 companies · $249 in 2025
The $249 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $32.46 · 2021: $14.33 · 2022: $478 · 2023: $242 · 2024: $297 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $788.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $318.39 | 2022 | |
| Novartis Pharmaceuticals Corporation | $203.82 | 2019-2025 | |
| Boston Scientific Corporation | $151.77 | 2023-2024 | Watchman Access System, Watchman Flx |
| Heartflow, INC. | $129.33 | 2025 | |
| Amgen INC. | $105.80 | 2019-2025 | Repatha, Repatha |
| Getinge USA Sales, LLC | $68.71 | 2019 | |
| Esperion Therapeutics, INC. | $53.53 | 2023-2024 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $52.44 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $47.89 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $46.43 | 2019-2021 | |
| Amarin Pharma, INC. | $43.67 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $41.75 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $41.44 | 2019-2025 | |
| Celltrion USA INC. | $39.05 | 2025 | Vegzelma |
| Recor Medical INC | $38.99 | 2024 | Paradise Renal Denervation System |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $29.19 | 2019 | |
| Pfizer INC. | $28.73 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $28.14 | 2019 | |
| Merck Sharp & Dohme LLC | $27.57 | 2022 | |
| Edwards Lifesciences Corporation | $24.81 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Alnylam Pharmaceuticals INC. | $18.75 | 2025 | Onpattro |
| Azurity Pharmaceuticals, INC. | $18.24 | 2023 | Edarbi |
| Lexicon Pharmaceuticals, INC. | $17.92 | 2024 | |
| Angiodynamics, INC. | $17.82 | 2019 | |
| Cardiovascular Systems INC. | $16.74 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.78 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.70 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amar Narula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.